ProQR Therapeutics Plans Virtual Analyst and Investor Event
ProQR Therapeutics N.V. (Nasdaq: PRQR) is excited to announce a forthcoming virtual Analyst and Investor Event. This event is set to convene on a Wednesday from 10:00 am to approximately 12:30 pm EST. It aims to provide investors and analysts with key insights into ProQR's innovative RNA therapies and ongoing developments in their product pipeline.
Highlighting the Axiomer™ Platform
During the session, the focus will be on ProQR's proprietary Axiomer™ ADAR-mediated RNA editing platform. This advanced technology is designed to enable precise and targeted modifications in RNA, opening the door to potentially groundbreaking treatments for a range of diseases, including genetic disorders that currently lack effective therapies. Attendees will gain a clearer understanding of how this platform can address unmet medical needs through innovative treatment approaches.
Pipeline Developments and Key Updates
The event will delve into updates on ProQR's pipeline of development candidates. Detailed insights will be shared on various programs, including the latest data updates and upcoming steps regarding NTCP, B4GALT1, AX-0810, and AX-1412. The Management Team, comprising Daniel A. de Boer (Founder and CEO) and Gerard Platenburg (Chief Scientific Officer), will lead the discussions. René Beukema, Chief Corporate Development Officer, will also participate in the analyst Q&A session, enhancing the dialogue with valuable insights.
Notable Speakers Joining the Event
In addition to ProQR’s Management Team, esteemed speakers will present their knowledge and perspectives. Peter Beal, PhD, a Professor at the University of California at Davis and Director of the NIH-funded UC Davis Chemical Biology Graduate Program, will discuss how ADAR innovation drives advancements in RNA therapies. His experiences are likely to provide enlightening viewpoints on the current trends and breakthroughs in the field.
Expert Insights from Prof. Gideon Hirschfield
Furthermore, Prof. Gideon Hirschfield, a notable figure specializing in autoimmune liver diseases, will express his views regarding the unmet needs in the therapeutic landscape, particularly concerning AX-0810. His extensive experience, backed by his role at the Toronto Centre for Liver Disease, qualifies him as a vital source of information regarding current and future needs in healthcare.
Registration and Participation
For those interested in attending the live webcast of the event, registration is encouraged. The event details and registration information are available on ProQR's website under the “Investors & Media” section. Participants can also join the live call via phone, with dedicated dial-in details included in the registration process. It is advisable for attendees to connect to the conference call at least 15 minutes prior to the scheduled start time to ensure smooth participation.
Archived Webcast and Future Access
Post-event, an archived version of the webcast will be accessible on ProQR’s website for around 30 days. This allows interested parties who are unable to attend the live event to catch up on the key information and insights shared by the company and its guest speakers.
Understanding Axiomer™ Technology
ProQR Therapeutics is at the forefront of RNA-based therapies with their next-generation RNA base editing technology known as Axiomer™. This innovative approach leverages the molecular machinery naturally present in human cells to make precise edits within RNA. By facilitating single nucleotide changes, Axiomer™ aims to correct genetic mutations that lead to various diseases, potentially revolutionizing the treatment landscape for countless patients.
About ProQR Therapeutics
ProQR is deeply committed to transforming lives through the development of pioneering RNA therapies. By utilizing their unique RNA editing technologies, they strive to produce effective treatments for both rare and widespread diseases. With a strong focus on patient needs and a dedication to innovative science, ProQR is cultivating a robust pipeline that promises to address significant medical challenges.
Frequently Asked Questions
What is ProQR Therapeutics focusing on in their upcoming event?
ProQR is set to highlight its RNA editing technology, particularly the Axiomer™ platform, along with updates on its development pipeline.
Who are the main speakers at the event?
The event will feature key speakers including ProQR's management team and notable experts like Peter Beal, PhD, and Prof. Gideon Hirschfield.
How can I register for the virtual event?
Interested participants can register for the event through ProQR's website, where details are provided in the Investors & Media section.
Will there be a way to access the event after it concludes?
Yes, the event will be available for replay on ProQR’s website for approximately 30 days following the live session.
What innovations does ProQR’s Axiomer™ platform bring to RNA therapy?
Axiomer™ allows for specific single nucleotide edits in RNA, which could potentially reverse mutations or alter protein expressions linked to various diseases.
